Alongside Enhertu, Daiichi and AstraZeneca's Datroway also showed a 43% reduction in risk of progression or death, marking continued progress in breast cancer treatment. The survival benefit was seen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback